DonDonDonDon, I've spend hours and hours on the 'clinicaltrials' website and me findings are that:
A) it is always updated to late to be useful in trading decisions (it is of course not intended for that :)
B) I never, ever, had a case as you describe where something happened before the indicated date in small companies. It was always to later unless for some BP sponsored trials.
C) The market always does the OPOSIT of the results if some trading entity is in the know. And surprises are never far away.
I can illustrate this last statement with several CDMO (at the time PPHM) clinical trials. PPS huge up, bad news, sudden drop to take away EVERY opportunity to get out quickly, unless at great loss or if you are lucky sitting it out over years.
In that aspect, if you are correct about the HGEN topline data, we'll see HGEN be pulled under 2$ (because the market wants you to sell cheap if the next event will drive the PPS up big time). Just as it will want you to buy expensive (by bringing the PPS up) when the next event is bad news that will kill the PPS suddenly on the news.
So, HGEN being at a new low yesterday may mean that you could have some good news coming, because many other pharma/biotech stocks started their climb out of the correction dip. If you are correct, then IMO, the golden cakes might be available near 1$ before the model jumps out of the cake.
I wanted to buy at 2.25$ (which was my expected bottom PPS that I predicted months ago, just after the Lenz failure when the PPS was just below 7$). I am going to wait a little before getting in again because my little voice says we might indeed get a surprise from non-US approvals. That will give the PPS a short boost, which will not last because Lenz can no longer at this point be rentabilized in the Covid market as it could have with an FDA approval many months ago. But IMO it could be possible that on such news, if the PPS is near 1$ the leverage will be between x2 to x5 on a very short period.
AIMO
News 
Market Data 
Discover 
AI
